Symbol
| DAB2IP
| contributors: mct/pgu - updated : 13-02-2010
|
HGNC name
| DAB2 interacting protein
|
HGNC id
| 17294
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --low
|  
|
in prostate cancer | tumoral
| fusion
| translocation
|  
|  
|
fused with MLL in t(9;11) (q34;q23) in acute myeloid leukemia | tumoral
|  
|  
|  
|  
|
leads to imbalance of cell survival and apoptosis pathways, which plays a significant role in tumor development | |
Susceptibility
|
to aggressive prostate cancer to early onset myocardial infarction, peripheral arterial disease, abdominal aortic aneurysms and pulmonary embolism |
Variant & Polymorphism
SNP
| in the DAB2IP gene is associated with risk of aggressive prostate cancer (PCa), and loss of DAB2IP expression is frequently detected in metastatic PCa |
|
rs7025486[A] is associated with early onset myocardial infarction, peripheral arterial disease, abdominal aortic aneurysms and pulmonary embolism |
|
|
Candidate gene
Marker
| assessment of DAB2IP may provide a prognostic biomarker in prostate carcinoma metastasis | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | metastases | | |
potential therapeutic target for Prostate Carcinoma metastasis |
| | |
| AIP1-deficient mice (AIP1-KO) | |
Dab2IP knock-down mice did not exhibit severe ataxia or cerebellar hypoplasia, but Dab2IP deficiency produced a number of cerebellar abnormalities such as a delay in the development of Purkinje cell (PC) dendrites |